U.S. markets closed
  • S&P Futures

    4,159.50
    -5.25 (-0.13%)
     
  • Dow Futures

    33,981.00
    -35.00 (-0.10%)
     
  • Nasdaq Futures

    13,904.50
    -14.75 (-0.11%)
     
  • Russell 2000 Futures

    2,229.40
    -9.00 (-0.40%)
     
  • Crude Oil

    61.10
    -0.25 (-0.41%)
     
  • Gold

    1,793.50
    +0.40 (+0.02%)
     
  • Silver

    26.58
    +0.01 (+0.02%)
     
  • EUR/USD

    1.2044
    +0.0004 (+0.04%)
     
  • 10-Yr Bond

    1.5640
    +0.0020 (+0.13%)
     
  • Vix

    17.50
    -1.18 (-6.32%)
     
  • GBP/USD

    1.3940
    +0.0008 (+0.05%)
     
  • USD/JPY

    108.0000
    -0.0430 (-0.04%)
     
  • BTC-USD

    53,429.71
    -2,775.22 (-4.94%)
     
  • CMC Crypto 200

    1,230.38
    -32.58 (-2.58%)
     
  • FTSE 100

    6,895.29
    +35.42 (+0.52%)
     
  • Nikkei 225

    29,096.11
    +587.56 (+2.06%)
     

Cipher Pharmaceuticals Appoints New Chief Financial Officer

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

OAKVILLE, ON , July 2, 2020 /CNW/ - Cipher Pharmaceuticals Inc. (CPH.TO) ("Cipher" or "the Company") is pleased to announce that it has appointed seasoned Financial Executive Scott Langille as its new Chief Financial Officer (CFO), he will succeed Interim CFO Nadine Jutlah .

Mr. Langille brings with him an extensive background in corporate and operational finance with strong experience in both branded and generic pharmaceuticals, medical devices and biotechnology. Mr. Langille has held senior roles at Tribute Pharmaceuticals, ViRexx Medical Corp, Zimmer Holdings, Verum Pharmaceuticals and Biovail Corporation.

"We are excited to welcome Scott to Cipher," said Mr. Craig Mull , Interim CEO. "Scott brings nearly 20 years of senior leadership roles with a solid focus on life sciences. Scott's tenure as the CFO and founding member of Tribute Pharmaceuticals and his direct involvement with product acquisitions, licensing and development deals will be invaluable to Cipher as we continue to right-size the business and look for opportunities for growth. "

"I look forward to working closely with Management and the Board during this exciting time," said Mr. Langille. "Cipher has already taken substantial costs out of the business, which has improved operating leverage and profitability. I am excited to contribute to the strategic direction of the Company as we continue to look for the right opportunities for long term growth."

About Cipher Pharmaceuticals Inc.

Cipher Pharmaceuticals (CPH.TO) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and currently markets those products either directly in Canada or indirectly through partners in Canada, the U.S., and South America. For more information, visit www.cipherpharma.com.

Forward-Looking Statements

This document includes forward-looking statements within the meaning of applicable securities laws. These forward-looking statements include, among others, statements with respect to our objectives and goals and strategies to achieve those objectives and goals, as well as statements with respect to our beliefs, plans, expectations, anticipations, estimates and intentions and statements relating to the Special Committee's review of the strategic direction of the Company and its strategic priorities including the anticipated benefits thereof. The words "may", "will", "could", "should", "would", "suspect", "outlook", "believe", "plan", "anticipate", "estimate", "expect", "intend", "forecast", "objective", "hope", "look" and "continue" (or the negative thereof), and words and expressions of similar import, are intended to identify forward-looking statements.

By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, which give rise to the possibility that predictions, forecasts, projections and other forward-looking statements will not be achieved. Certain material factors or assumptions are applied in making forward-looking statements and actual results may differ materially from those expressed or implied in such statements. We caution readers not to place undue reliance on these statements as a number of important factors, many of which are beyond our control, could cause our actual results to differ materially from the beliefs, plans, objectives, expectations, anticipations, estimates and intentions expressed in such forward-looking statements. These factors include, but are not limited to, the extent and impact of the coronavirus (COVID-19) outbreak on our business including any impact on our contract manufacturers and other third party service providers, our ability to enter into development, manufacturing and marketing and distribution agreements with other pharmaceutical companies and keep such agreements in effect; our dependency on a limited number of products; our dependency on protection from patents that will expire; integration difficulties and other risks if we acquire or in-license technologies or product candidates; reliance on third parties for the marketing of certain products; the product approval process is highly unpredictable; the timing of completion of clinical trials, regulatory submissions and regulatory approvals; reliance on third parties to manufacture our products and events outside of our control that could adversely impact the ability of our manufacturing partners to supply products to meet our demands; we may be subject to future product liability claims; unexpected product safety or efficacy concerns may arise; we generate license revenue from a limited number of distribution and supply agreements; the pharmaceutical industry is highly competitive; requirements for additional capital to fund future operations; products in Canada may be subject to pricing regulation; dependence on key managerial personnel and external collaborators; no assurance that we will receive regulatory approvals in the U.S., Canada or any other jurisdictions and current uncertainty surrounding health care regulation in the U.S.; certain of our products are subject to regulation as controlled substances; limitations on reimbursement in the healthcare industry; limited reimbursement for products by government authorities and third-party payor policies; products may not be included on list of drugs approved for use in hospitals; hospital customers may make late payments or not make any payments; various laws pertaining to health care fraud and abuse; reliance on the success of strategic investments and partnerships; the publication of negative results of clinical trials; unpredictable development goals and projected time frames; rising insurance costs; ability to enforce covenants not to compete; risks associated with the industry in which we operate; we may be unsuccessful in evaluating material risks involved in completed and future acquisitions; we may be unable to identify, acquire or integrate acquisition targets successfully; legacy risks from operations conducted in the U.S.; inability to meet covenants under our long term debt arrangement; compliance with privacy and security regulation; our policies regarding returns, allowances and chargebacks may reduce revenues; certain current and future regulations could restrict our activities; additional regulatory burden and controls over financial reporting; reliance on third parties to perform certain services; general commercial litigation, class actions, other litigation claims and regulatory actions; the difficulty for shareholders to realize in the United States upon judgments of U.S. courts predicated upon civil liability of the Company and its directors and officers who are not residents of the United States ; the potential violation of intellectual property rights of third parties; our efforts to obtain, protect or enforce our patents and other intellectual property rights related to our products; changes in U.S., Canadian or foreign patent laws; litigation in the pharmaceutical industry concerning the manufacture and supply of novel and generic versions of existing drugs; inability to protect our trademarks from infringement; shareholders may be further diluted if we issue securities to raise capital; volatility of our share price; the fact that we have a significant shareholder; we do not currently intend to pay dividends; our operating results may fluctuate significantly; and our debt obligations will have priority over the common shares of the Company in the event of a liquidation, dissolution or winding up.

We caution that the foregoing list of important factors that may affect future results is not exhaustive. When reviewing our forward-looking statements, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. Additional information about factors that may cause actual results to differ materially from expectations, and about material factors or assumptions applied in making forward-looking statements, may be found in the "Risk Factors" section of this MD&A and the Annual Information Form for the year ended December 31, 2019 , and elsewhere in our filings with Canadian securities regulators. Except as required by Canadian securities law, we do not undertake to update any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf; such statements speak only as of the date made. The forward-looking statements included herein are expressly qualified in their entirety by this cautionary language.

SOURCE Cipher Pharmaceuticals Inc.

Cision
Cision

View original content: http://www.newswire.ca/en/releases/archive/July2020/02/c0341.html